These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18424917)

  • 1. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
    Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
    Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
    Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
    J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
    Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
    J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.
    Molli PR; Adam L; Kumar R
    Clin Cancer Res; 2008 Oct; 14(19):6161-70. PubMed ID: 18829495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.
    Saleh MN; Raisch KP; Stackhouse MA; Grizzle WE; Bonner JA; Mayo MS; Kim HG; Meredith RF; Wheeler RH; Buchsbaum DJ
    Cancer Biother Radiopharm; 1999 Dec; 14(6):451-63. PubMed ID: 10850332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.
    Schechter NR; Yang DJ; Azhdarinia A; Kohanim S; Wendt R; Oh CS; Hu M; Yu DF; Bryant J; Ang KK; Forster KM; Kim EE; Podoloff DA
    Anticancer Drugs; 2003 Jan; 14(1):49-56. PubMed ID: 12544258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
    Modjtahedi H; Styles JM; Dean CJ
    Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cetuximab and fractionated irradiation on tumour micro-environment.
    Santiago A; Eicheler W; Bussink J; Rijken P; Yaromina A; Beuthien-Baumann B; van der Kogel AJ; Baumann M; Krause M
    Radiother Oncol; 2010 Nov; 97(2):322-9. PubMed ID: 20667608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.
    Prewett M; Rockwell P; Rockwell RF; Giorgio NA; Mendelsohn J; Scher HI; Goldstein NI
    J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):419-27. PubMed ID: 9041461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
    Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
    J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.